Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05609916 · ClinicalTrials.gov registry record · NA
CBT Augmentation to Promote Medication Discontinuation in Pediatric OCD
A NA study of Obsessive - Compulsive Disorder and Cognitive Behavioral Therapy, sponsored by Baylor College of Medicine.
- Recruiting
- Registry status
- NA
- Development phase
- 200
- Enrollment target
- 1
- Study location
NCT05609916: Recruiting NA study of Obsessive - Compulsive Disorder and Cognitive Behavioral Therapy, sponsored by Baylor College of Medicine.
NCT05609916 is a NA study of Obsessive - Compulsive Disorder and Cognitive Behavioral Therapy that is actively recruiting participants, run by Baylor College of Medicine. The registered enrollment target is 200 participants, below the 2,062-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (90% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05609916, a NA study of Obsessive - Compulsive Disorder and Cognitive Behavioral Therapy, is actively recruiting participants, sponsored by Baylor College of Medicine.
- RECRUITING
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to examine whether youth with OCD who benefit from CBT augmentation to SRI can discontinue their medication without relapse over 24 weeks.
Primary Outcome
Clinician-rated child OCD symptoms and severity throughout the past week. The scale has a checklist of obsessions and compulsions, followed by severity items each scored on a 0 to 4 scale.
Conditions Studied
Interventions
- BEHAVIORAL Cognitive Behavioral Therapy
Study Locations (1)
Texas
- Baylor College of Medicine - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2022-11-30 |
| Est. Completion | 2027-08-30 |
| Phase | NA |
What NCT05609916 shows while recruiting
NCT05609916 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 2,062-participant average among 84 other Obsessive - Compulsive Disorder trials with a reported enrollment target (90% lower).
The record links to 4 conditions, with Obsessive - Compulsive Disorder appearing as the primary indexed condition, and to 1 intervention - of which Cognitive Behavioral Therapy is the first listed.
NCT05609916 reports a single indexed study location in Texas.
Frequently Asked Questions
What is clinical trial NCT05609916 about?
NCT05609916 is a clinical study titled "CBT Augmentation to Promote Medication Discontinuation in Pediatric OCD". The purpose of this study is to examine whether youth with OCD who benefit from CBT augmentation to SRI can discontinue their medication without relapse over 24 weeks.
What is the current status of trial NCT05609916?
This trial is currently recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2022-11-30. Estimated completion is 2027-08-30.
What conditions does trial NCT05609916 study?
This clinical trial studies the following conditions: Obsessive - Compulsive Disorder, Cognitive Behavioral Therapy, Obsessive-Compulsive Disorder in Children, Obsessive-Compulsive Disorder in Adolescence.
What interventions are being tested in trial NCT05609916?
The interventions under investigation include: Cognitive Behavioral Therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT05609916?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05609916 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obsessive - Compulsive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05609916's enrollment target sits among peer trials
200 18th of 84 higher than 67 of 84 other Obsessive - Compulsive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Obsessive - Compulsive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Transcranial Magnetic Stimulation and Psychotherapy for Treating Obsessive-Compulsive Disorder
RECRUITING · NA
-
Mechanisms of Exposure Therapy for OCD
RECRUITING · NA
-
Using Personalized Assessments in the Treatment of Childhood OCD
RECRUITING · NA
-
Neural Mechanisms of Response Inhibition Training for OCRD
RECRUITING · NA
-
CO2 Reactivity as a Biomarker of Non-Response to Exposure-Based Therapy
RECRUITING · NA
-
Interpretation Bias as a Mechanism of Treatment Response in OCD
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI